ExploreWatchlistsPricing
  1. JP-listed companies
  2. Momotaro-Gene Inc.
  3. Financials
  4. Common stock and paid-in capital

Momotaro-Gene Inc. (E33052)

Market cap
P/E ratio
Momotaro Genen develops innovative gene therapy drugs using the REIC cancer suppressor gene discovered at Okayama University to selectively kill cancer cells.
SummaryFinancialsDividendsHistoryWorkforce
Period EndCommon stock and paid-in capital (Million JPY)YoY (%)
Mar 31, 20232,541+0.00%
Mar 31, 20222,541+0.00%
Mar 31, 20212,541+4.09%
Mar 31, 20202,441+0.00%
Mar 31, 20192,441+27.06%
Mar 31, 20181,921+14.82%
Mar 31, 20171,673+129.55%
Mar 31, 2016729+55.70%
Mar 31, 2015468+8.58%
Mar 31, 2014431+0.00%
Mar 31, 2013431+4.36%
Mar 31, 2012413+5.14%
Mar 31, 2011393+42.60%
Mar 31, 2010276+66.02%
Mar 31, 2009166

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat